Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment…
By A. Falcone, S. Ricci, I. Brunetti, E. Pfanner, G. Allegrini, C. Barbara, L. Crinò, G. Benedetti, W. Evangelista, L. Fanchini and 10 more. Journal of Clinical Oncology, 2007
1,161 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/d66b6edcb2c22b0976ef4444b7fb112199398592
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019, neutral): “In BRAF‑mutated colorectal can‑ cer, FOLFOXIRI + BEV combination therapy has shown high efficacy.”
- Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2014, result): “The data on triplet combination cytotoxic treatment with 5-FU, oxaliplatin and irinotecan are interesting, but remain controversial: an Italian randomised phase III study showed a better outcome for patients treated with FOLFOXIRI compared with FOLFIRI, while a Greek study did not show any differenc”
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, methodology): “Also, consideration of the other available data from these studies [176, 177, 180] clearly shows both FOLFOX and FOLFIRI to be active in combination with EGFR inhibitors in patients with RAS wild-type disease in this treatment setting, while FOLFOXIRI plus (or minus) bevacizumab has been shown to be”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer (2015, neutral): “• FOLFOX note 1 [57, 58] +Bmab [54] • CapeOX note 2 + Bmab [59, 60] • FOLFIRI note 3 [61, 62] +Bmab [63, 64] • FOLFOX + Cmab/Pmab [65, 66] • FOLFIRI + Cmab/Pmab [67, 68] • FOLFOXIRI note 4 [69] • Infusional 5-FU + l-LV [70, 71] +Bmab [72, 73] • Cape [74, 75] + Bmab [76] • UFT + LV [77–79]”
- Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012, neutral): “• FOLFOX (note 1) [57, 58] + Bmab [54] • CapeOX (note 2) + Bmab [59, 60] ▪ SOX + Bmab (note 3) [61] • FOLFIRI (note 4) [62, 63] + Bmab [64, 65] • FOLFOX + Cmab/Pmab [66, 67] • FOLFIRI + Cmab/Pmab [68, 69] • FOLFOXIRI (note 5) [70] ▪ FOLFOXIRI + Bmab [71, 72] • Infusional 5-FU + LV [73, 74] + Bma”